These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

516 related articles for article (PubMed ID: 33859761)

  • 21. IgG-Binding Nanobody Capable of Prolonging Nanobody-Based Radiotracer Plasma Half-Life and Enhancing the Efficacy of Tumor-Targeted Radionuclide Therapy.
    Hu B; Liu T; Li L; Shi L; Yao M; Li C; Ma X; Zhu H; Jia B; Wang F
    Bioconjug Chem; 2022 Jul; 33(7):1328-1339. PubMed ID: 35687724
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of Dye and Conjugation Chemistry on the Biodistribution Profile of Near-Infrared-Labeled Nanobodies as Tracers for Image-Guided Surgery.
    Debie P; Van Quathem J; Hansen I; Bala G; Massa S; Devoogdt N; Xavier C; Hernot S
    Mol Pharm; 2017 Apr; 14(4):1145-1153. PubMed ID: 28245129
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rapid optical imaging of human breast tumour xenografts using anti-HER2 VHHs site-directly conjugated to IRDye 800CW for image-guided surgery.
    Kijanka M; Warnders FJ; El Khattabi M; Lub-de Hooge M; van Dam GM; Ntziachristos V; de Vries L; Oliveira S; van Bergen En Henegouwen PM
    Eur J Nucl Med Mol Imaging; 2013 Oct; 40(11):1718-29. PubMed ID: 23778558
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Radionuclide therapy using ABD-fused ADAPT scaffold protein: Proof of Principle.
    Garousi J; von Witting E; Borin J; Vorobyeva A; Altai M; Vorontsova O; Konijnenberg MW; Oroujeni M; Orlova A; Tolmachev V; Hober S
    Biomaterials; 2021 Jan; 266():120381. PubMed ID: 33120197
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Selective Cytotoxicity to HER2 Positive Breast Cancer Cells by Saporin-Loaded Nanobody-Targeted Polymeric Nanoparticles in Combination with Photochemical Internalization.
    Martínez-Jothar L; Beztsinna N; van Nostrum CF; Hennink WE; Oliveira S
    Mol Pharm; 2019 Apr; 16(4):1633-1647. PubMed ID: 30817164
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Affibody-derived drug conjugates: Potent cytotoxic molecules for treatment of HER2 over-expressing tumors.
    Altai M; Liu H; Ding H; Mitran B; Edqvist PH; Tolmachev V; Orlova A; Gräslund T
    J Control Release; 2018 Oct; 288():84-95. PubMed ID: 30172673
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeted radionuclide therapy with A 177Lu-labeled anti-HER2 nanobody.
    D'Huyvetter M; Vincke C; Xavier C; Aerts A; Impens N; Baatout S; De Raeve H; Muyldermans S; Caveliers V; Devoogdt N; Lahoutte T
    Theranostics; 2014; 4(7):708-20. PubMed ID: 24883121
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synthesis, preclinical validation, dosimetry, and toxicity of 68Ga-NOTA-anti-HER2 Nanobodies for iPET imaging of HER2 receptor expression in cancer.
    Xavier C; Vaneycken I; D'huyvetter M; Heemskerk J; Keyaerts M; Vincke C; Devoogdt N; Muyldermans S; Lahoutte T; Caveliers V
    J Nucl Med; 2013 May; 54(5):776-84. PubMed ID: 23487015
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Novel Platinum(II)-Based Bifunctional ADC Linker Benchmarked Using 89Zr-Desferal and Auristatin F-Conjugated Trastuzumab.
    Sijbrandi NJ; Merkul E; Muns JA; Waalboer DC; Adamzek K; Bolijn M; Montserrat V; Somsen GW; Haselberg R; Steverink PJ; Houthoff HJ; van Dongen GA
    Cancer Res; 2017 Jan; 77(2):257-267. PubMed ID: 27872093
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HER2-targeted antibody drug conjugates for ovarian cancer therapy.
    Jiang J; Dong L; Wang L; Wang L; Zhang J; Chen F; Zhang X; Huang M; Li S; Ma W; Xu Q; Huang C; Fang J; Wang C
    Eur J Pharm Sci; 2016 Oct; 93():274-86. PubMed ID: 27509865
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of [
    Ducharme M; Hall L; Eckenroad W; Cingoranelli SJ; Houson HA; Jaskowski L; Hunter C; Larimer BM; Lapi SE
    Mol Pharm; 2023 Sep; 20(9):4629-4639. PubMed ID: 37552575
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Precision Chemoradiotherapy for HER2 Tumors Using Antibody Conjugates of an Auristatin Derivative with Reduced Cell Permeability.
    Hingorani DV; Doan MK; Camargo MF; Aguilera J; Song SM; Pizzo D; Scanderbeg DJ; Cohen EEW; Lowy AM; Adams SR; Advani SJ
    Mol Cancer Ther; 2020 Jan; 19(1):157-167. PubMed ID: 31597712
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Target-specific cytotoxic effects on HER2-expressing cells by the tripartite fusion toxin ZHER2:2891-ABD-PE38X8, including a targeting affibody molecule and a half-life extension domain.
    Liu H; Seijsing J; Frejd FY; Tolmachev V; Gräslund T
    Int J Oncol; 2015 Aug; 47(2):601-9. PubMed ID: 26046132
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fluorine-18 Labeling of the HER2-Targeting Single-Domain Antibody 2Rs15d Using a Residualizing Label and Preclinical Evaluation.
    Zhou Z; Vaidyanathan G; McDougald D; Kang CM; Balyasnikova I; Devoogdt N; Ta AN; McNaughton BR; Zalutsky MR
    Mol Imaging Biol; 2017 Dec; 19(6):867-877. PubMed ID: 28409338
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase I Study of 68Ga-HER2-Nanobody for PET/CT Assessment of HER2 Expression in Breast Carcinoma.
    Keyaerts M; Xavier C; Heemskerk J; Devoogdt N; Everaert H; Ackaert C; Vanhoeij M; Duhoux FP; Gevaert T; Simon P; Schallier D; Fontaine C; Vaneycken I; Vanhove C; De Greve J; Lamote J; Caveliers V; Lahoutte T
    J Nucl Med; 2016 Jan; 57(1):27-33. PubMed ID: 26449837
    [TBL] [Abstract][Full Text] [Related]  

  • 36.
    Zhao L; Gong J; Qi Q; Liu C; Su H; Xing Y; Zhao J
    Int J Nanomedicine; 2023; 18():1915-1925. PubMed ID: 37064291
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Design optimization and characterization of Her2/neu-targeted immunotoxins: comparative in vitro and in vivo efficacy studies.
    Cao Y; Marks JW; Liu Z; Cheung LH; Hittelman WN; Rosenblum MG
    Oncogene; 2014 Jan; 33(4):429-39. PubMed ID: 23376850
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Astatine-211 labeled anti-HER2 5F7 single domain antibody fragment conjugates: radiolabeling and preliminary evaluation.
    Choi J; Vaidyanathan G; Koumarianou E; Kang CM; Zalutsky MR
    Nucl Med Biol; 2018 Jan; 56():10-20. PubMed ID: 29031230
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design and biological evaluation of novel long-acting adalimumab Fab conjugated with the albumin binding domain.
    Zhang Q; Qian M; Wu Y; Wang Y; Shangguan W; Lu J; Zhao W; Feng J
    Eur J Pharmacol; 2021 Aug; 904():174152. PubMed ID: 33964292
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PD-L1/TLR7 dual-targeting nanobody-drug conjugate mediates potent tumor regression via elevating tumor immunogenicity in a host-expressed PD-L1 bias-dependent way.
    Yu X; Long Y; Chen B; Tong Y; Shan M; Jia X; Hu C; Liu M; Zhou J; Tang F; Lu H; Chen R; Xu P; Huang W; Ren J; Wan Y; Sun J; Li J; Jin G; Gong L
    J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36253000
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.